-
physiology and pathogenesis. 2) Development of novel drugs to treat MASH, diabetes, and cancer. For more information on Dr. Wendong Huang’s research, please visit here . Your qualifications should include
-
top journals such as Journal of Hematology & Oncology (2024), Cancer Research (2024), Cell (2023), Cell Stem Cell (2023 ×2), and Nature Cell Biology (2022). The Su research program is currently
-
) development of small molecule drugs and PROTAC-drug conjugates. The Li group conducts the most forefront science and is highly productive with publications in high-impact journals in the past five years, Nature
-
Oncology, JNCI, Clinical Cancer Research, Nature Communications, Nature Reviews Gastroenterology and Hepatology, Annals of Surgery, etc. If you are passionate about some of the following things we
-
Medicine, and member of the City of Hope Comprehensive Cancer. The Perry laboratory uses structural biology approaches, together with small molecule and fragment-based drug discovery, computer-aided drug
-
solid cancers. We are especially interested in therapeutic strategies that exploit mitochondrial vulnerabilities, including the use of nucleoside analogs, small GTPase inhibitors, natural plant-derived
-
of transplants, and single-cell and spatial multi-omics. Our research has been published in esteemed journals such as Science, Nature Medicine, Nature Cell Biology, Cell Metabolism, and the Journal of Clinical
-
epitope selection pipelines. · Experience in molecular virology methods, and antigen presentation and processing as applied to human and murine oncology. · Ability to independently document
-
candidate, you will: · You must have experience with flow cytometry, molecular biology techniques, cell culture, microscopy, tissue processing, immunohistochemistry, immunofluorescence, data analysis